Market Cap 567.62M
Revenue (ttm) 332.07M
Net Income (ttm) 18.25M
EPS (ttm) N/A
PE Ratio 38.90
Forward PE N/A
Profit Margin 5.50%
Debt to Equity Ratio 0.02
Volume 231,000
Avg Vol 467,676
Day's Range N/A - N/A
Shares Out 28.87M
Stochastic %K 21%
Beta 1.10
Analysts Strong Sell
Price Target $35.89

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 866 788 9007
Address:
505 S. Friendswood Drive, Suite 401, Friendswood, United States
JMacDad
JMacDad Jul. 12 at 9:10 PM
$CSTL Terrible stock, bought several years ago and lost big time despite rosey ($90) forecasts. Terrible short or long hold. Get out and don't do business with this mismanaged company.
0 · Reply
Newcar
Newcar Jun. 18 at 4:08 PM
0 · Reply
Dream2121
Dream2121 Jun. 18 at 1:01 PM
$CSTL This will be above $20 before ER. Hugely undervalued.
0 · Reply
Newcar
Newcar Jun. 18 at 10:32 AM
$CSTL Revenues will soon be higher than market cap. Undervalued!!!!!
2 · Reply
Newcar
Newcar Jun. 17 at 3:17 PM
$CSTL undervalued company
0 · Reply
Newcar
Newcar Jun. 17 at 2:19 PM
$CSTL good news. Today speculation
0 · Reply
prismmarketview
prismmarketview Jun. 17 at 1:49 PM
$CSTL is expanding into atopic dermatitis diagnostics through a new partnership with SciBase. The goal: develop a test to predict AD flares before symptoms appear. Aimed at a U.S. patient base of up to 24M. #CastleBiosciences https://prismmarketview.com/castle-biosciences-expands-into-atopic-dermatitis-diagnostics-with-new-scibase-partnership/
0 · Reply
Leadballoon
Leadballoon Jun. 16 at 3:13 PM
$CSTL Let's go MaetSOLD it's poking it's head up, flail away at the printer and sell those free shares.
0 · Reply
Dream2121
Dream2121 Jun. 9 at 3:41 PM
0 · Reply
Newcar
Newcar Jun. 5 at 2:52 PM
$CSTL real value $50👍
1 · Reply
Latest News on CSTL
Castle Biosciences Celebrates Skin Cancer Awareness Month

May 7, 2025, 7:00 AM EDT - 2 months ago

Castle Biosciences Celebrates Skin Cancer Awareness Month


Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:58 PM EDT - 2 months ago

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript


Castle Biosciences Reports First Quarter 2025 Results

May 5, 2025, 4:06 PM EDT - 2 months ago

Castle Biosciences Reports First Quarter 2025 Results


Castle Biosciences to Acquire Previse

May 5, 2025, 4:05 PM EDT - 2 months ago

Castle Biosciences to Acquire Previse


Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:09 PM EST - 4 months ago

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript


Castle Biosciences Reports Third Quarter 2024 Results

Nov 4, 2024, 4:05 PM EST - 9 months ago

Castle Biosciences Reports Third Quarter 2024 Results


JMacDad
JMacDad Jul. 12 at 9:10 PM
$CSTL Terrible stock, bought several years ago and lost big time despite rosey ($90) forecasts. Terrible short or long hold. Get out and don't do business with this mismanaged company.
0 · Reply
Newcar
Newcar Jun. 18 at 4:08 PM
0 · Reply
Dream2121
Dream2121 Jun. 18 at 1:01 PM
$CSTL This will be above $20 before ER. Hugely undervalued.
0 · Reply
Newcar
Newcar Jun. 18 at 10:32 AM
$CSTL Revenues will soon be higher than market cap. Undervalued!!!!!
2 · Reply
Newcar
Newcar Jun. 17 at 3:17 PM
$CSTL undervalued company
0 · Reply
Newcar
Newcar Jun. 17 at 2:19 PM
$CSTL good news. Today speculation
0 · Reply
prismmarketview
prismmarketview Jun. 17 at 1:49 PM
$CSTL is expanding into atopic dermatitis diagnostics through a new partnership with SciBase. The goal: develop a test to predict AD flares before symptoms appear. Aimed at a U.S. patient base of up to 24M. #CastleBiosciences https://prismmarketview.com/castle-biosciences-expands-into-atopic-dermatitis-diagnostics-with-new-scibase-partnership/
0 · Reply
Leadballoon
Leadballoon Jun. 16 at 3:13 PM
$CSTL Let's go MaetSOLD it's poking it's head up, flail away at the printer and sell those free shares.
0 · Reply
Dream2121
Dream2121 Jun. 9 at 3:41 PM
0 · Reply
Newcar
Newcar Jun. 5 at 2:52 PM
$CSTL real value $50👍
1 · Reply
TheLearnerEarner
TheLearnerEarner May. 30 at 9:03 PM
$CSTL ✅ Healthcare - Small Cap - F-Score: 8/9 👑 Analysts: 8x buy rating 👨‍🔬 Intrinsic Value Potential: Excellent 💎 RSI: 35.07 (oversold bullish) 📊🐂 Highest Analysts Price Target: $40.00 (150% above Price) 🌟 Range (12m) $15.45 - $35.84 💰 Positive Free Cash Flow: Yes 🏧 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/CSTL/new-data-at-asco-2025-affirms-decision-dx-melanoma-s-ability-to-41kn1j62bobj.html
1 · Reply
Newcar
Newcar May. 28 at 1:57 PM
$CSTL The more it goes down, the more chance there will be to increase your position before the rise. I hope it will go to $10
0 · Reply
Newcar
Newcar May. 23 at 10:31 AM
$CSTL I'll wait until $10 to lower the average even though I don't think it will get there
1 · Reply
RocketThief
RocketThief May. 20 at 3:36 PM
$CSTL this fell to mid-teens around the same time last year and was at $30+ by late summer. Fundamentals are even better now, I expect history to repeat itself
0 · Reply
TheLearnerEarner
TheLearnerEarner May. 13 at 7:04 PM
$CSTL ✅ Healthcare - mid cap - 0.70x relative volume F-Score: 8/9 🏦👑 Analysts: 8x buy rating 👨‍🔬 Intrinsic Value Potential: Good 💎 RSI: 35.64 (oversold bullish) 📊🐂 Analysts Price Target: $37.75 - $44.00 (107% - 155% above Price) 🌟 Range (12m) $15.70 - $35.84 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/CSTL/real-world-study-confirms-long-term-performance-of-decision-dx-um-th2em3357yg7.html
0 · Reply
Armonica423
Armonica423 May. 10 at 9:34 PM
$CSTL Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
RocketThief
RocketThief May. 8 at 3:57 PM
$CSTL $LUNG adding to both (usual strategy of long but with swinging around core), neither should have dropped on earnings
0 · Reply
Leadballoon
Leadballoon May. 7 at 5:19 PM
$CSTL Good thing you dumped so much stock MaetSOLD, you dodged your own bullets.
0 · Reply
stockstelegraph
stockstelegraph May. 7 at 11:24 AM
📊 Analyst Actions – May 6, 2025: 🔹 $DASH: DA Davidson raises PT from $150$190, maintains Neutral (Tom White) 🔹 $F: Barclays bumps PT from $8$9, maintains Equal-Weight (Dan Levy) 🔹 $CART: Macquarie maintains Outperform with $55 PT (Ross Compton) 🔹 $CSTL: Lake Street lowers PT from $40$35 but keeps Buy (Thomas Flaten) #Stocks #AnalystRatings #WallStreet #Upgrades #Downgrades
0 · Reply
PenkeTrading
PenkeTrading May. 7 at 1:46 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Castle Biosciences Inc. Is that bullish or bearish? $CSTL #RsiOversold #NASDAQ
0 · Reply
JarvisFlow
JarvisFlow May. 6 at 11:30 PM
Lake Street has adjusted their stance on Castle Biosciences ( $CSTL ), setting the rating to Buy with a target price of 40 → 35.
0 · Reply
Big_Slick
Big_Slick May. 6 at 5:35 PM
$CSTL Time to move on from this donkey....
1 · Reply